Data Sheet (Cat.No.T7681)

TargetMol

AZD-5069

Chemical Properties



CAS No. : 878385-84-3

Formula: C18H22F2N4O5S2

Molecular Weight: 476.52

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	AZD-5069 is an chemokine receptor 2 antagonist (CXCR2; IC50 = 0.79 nM).
Targets(IC50)	CXCR
In vitro	AZD5069 inhibited neutrophil chemotaxis, with a pA2 of approximately 9.6, and adhesion molecule expression, with a pA2 of 6.9, in response to CXCL1[1]

Solubility Information

Solubility	DMSO: 250 mg/mL (524.64 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.93 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0985 mL	10.4927 mL	20.9855 mL
5 mM	0.4197 mL	2.0985 mL	4.1971 mL
10 mM	0.2099 mL	1.0493 mL	2.0985 mL
50 mM	0.042 mL	0.2099 mL	0.4197 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Nicholls D J , Wiley K , Dainty I , et al. Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist[J]. Journal of Pharmacology and Experimental Therapeutics, 2015, 353(2):340-350.

Norman, Peter. Evidence on the identity of the CXCR2 antagonist AZD-5069[J]. Expert Opinion on Therapeutic Patents, 2013, 23(1):113-117.